Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott settles large part of US Tricor antitrust litigation

This article was originally published in Scrip

Executive Summary

Abbott Laboratorieshas agreed to pay $184 million to settle antitrust litigation with direct purchasers (ie, retailers, wholesalers) and certain individual plaintiffs over formulation changes to the company's branded hypolipaemic Tricor (micronised fenofibrate), according to a filing with the US Securities and Exchange Commission. The plaintiffs, which included Teva Pharmaceutical Industries, alleged that, as generic companies were developing ANDAs for Tricor, Abbott responded by changing the formulation of the product, not to improve the product but simply to prevent generic formulations from becoming AB-rated for substitution with Tricor. Other similar suits filed by over a dozen state attorneys general remain outstanding (Scrip Online, April 2nd, 2008). Abbott denies wrongdoing, but said it settled to avoid the uncertainty of a trial outcome. Abbott has continuously maintained that all of the suits are without merit, and that it has provided patients with continuous improvements to Tricor – an approach that is perfectly legal.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts